Patient reported outcomes in adults with type 2 diabetes on basal insulin randomized to addition of mealtime pramlintide or rapid-acting insulin analogs.

Peyrot M, Rubin RR, Polonsky WH, Best JH

Current medical research and opinion1 May 2010Cited by 21 (Europe PMC)

PMID20199136DOI10.1185/03007991003634759PepBankPUB-20199136

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study15

9 results from studies that gave the peptide. 9 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with T2DM, diabetes distress measures did not differ significantly between pramlintide and rapid-acting insulin groups.
In plain wordsIn adults with T2DM, distress measures did not differ significantly between pramlintide and rapid-acting insulin groups.
Peptide
Pramlintide (Symlin)
Outcome
No significant changeDiabetes distress between groups
Study
n = 112
Comparator
Rapid-acting insulin analogs
Outcome group
Quality of life · Mental health and mood
Studied dose
120 microg · 24 weeksAs given in this study (human).
Source sentences
Summary
Between-group differences in DDS measures were not significant.
1 context sentence(design, population, supporting numbers)
Summary · context
In this 24-week open-label, multicenter study of adults with type 2 diabetes, mealtime pramlintide (PRAM) (120 microg fixed dose; n = 56) or titrated RAIAs (n = 56) was added to basal insulin therapy with or without oral antidiabetic medications.
Report a problemFND-2019913604
02HumanRandomized controlled trialEfficacy outcome
In adults with T2DM, pramlintide improved daytime dysfunction more than rapid-acting insulin analogs.
In plain wordsIn adults with T2DM, pramlintide improved daytime dysfunction more than rapid-acting insulin analogs.
Peptide
Pramlintide (Symlin)
Outcome
DecreaseDaytime dysfunction between groups
Study
n = 112
Comparator
Rapid-acting insulin analogs
Outcome group
Sleep · Sleep
Studied dose
120 microg · 24 weeksAs given in this study (human).
Source sentences
Summary
PRAM patients experienced significant improvement in sleep latency and daytime dysfunction, while RAIA patients did not; the difference between groups was significant for daytime dysfunction.
1 context sentence(design, population, supporting numbers)
Summary · context
In this 24-week open-label, multicenter study of adults with type 2 diabetes, mealtime pramlintide (PRAM) (120 microg fixed dose; n = 56) or titrated RAIAs (n = 56) was added to basal insulin therapy with or without oral antidiabetic medications.
Report a problemFND-2019913607
03HumanRandomized controlled trialEfficacy outcome
In adults with T2DM, DTSQ measures did not differ significantly between pramlintide and rapid-acting insulin groups.
In plain wordsIn adults with T2DM, treatment satisfaction measures did not differ significantly between pramlintide and rapid-acting insulin groups.
Peptide
Pramlintide (Symlin)
Outcome
No significant changeDTSQ measures between groups
Study
n = 112
Comparator
Rapid-acting insulin analogs
Outcome group
Quality of life · Mental health and mood
Studied dose
120 microg · 24 weeksAs given in this study (human).
Source sentences
Summary
Between-group differences in DTSQ measures were not significant.
1 context sentence(design, population, supporting numbers)
Summary · context
In this 24-week open-label, multicenter study of adults with type 2 diabetes, mealtime pramlintide (PRAM) (120 microg fixed dose; n = 56) or titrated RAIAs (n = 56) was added to basal insulin therapy with or without oral antidiabetic medications.
Report a problemFND-2019913611
04HumanRandomized controlled trialEfficacy outcome
In adults with T2DM, pramlintide produced better perceived weight control than rapid-acting insulin analogs.
In plain wordsIn adults with T2DM, pramlintide produced better perceived weight control than rapid-acting insulin analogs.
Peptide
Pramlintide (Symlin)
Outcome
IncreasePerceived weight control
Study
n = 112
Comparator
Rapid-acting insulin analogs
Outcome group
Quality of life · Mental health and mood
Studied dose
120 microg · 24 weeksAs given in this study (human).
Source sentences
Summary
PRAM patients experienced significantly better perceived weight and appetite control than RAIA patients.
1 context sentence(design, population, supporting numbers)
Summary · context
In this 24-week open-label, multicenter study of adults with type 2 diabetes, mealtime pramlintide (PRAM) (120 microg fixed dose; n = 56) or titrated RAIAs (n = 56) was added to basal insulin therapy with or without oral antidiabetic medications.
Report a problemFND-2019913614
05HumanRandomized controlled trialEfficacy outcome
In adults with T2DM, pramlintide produced better perceived appetite control than rapid-acting insulin analogs.
In plain wordsIn adults with T2DM, pramlintide produced better perceived appetite control than rapid-acting insulin analogs.
Peptide
Pramlintide (Symlin)
Outcome
IncreasePerceived appetite control
Study
n = 112
Comparator
Rapid-acting insulin analogs
Outcome group
Quality of life · Mental health and mood
Studied dose
120 microg · 24 weeksAs given in this study (human).
Source sentences
Summary
PRAM patients experienced significantly better perceived weight and appetite control than RAIA patients.
1 context sentence(design, population, supporting numbers)
Summary · context
In this 24-week open-label, multicenter study of adults with type 2 diabetes, mealtime pramlintide (PRAM) (120 microg fixed dose; n = 56) or titrated RAIAs (n = 56) was added to basal insulin therapy with or without oral antidiabetic medications.
Report a problemFND-2019913615
06HumanRandomized controlled trialEfficacy outcome
In adults with T2DM, total diabetes distress improved from baseline with pramlintide.
In plain wordsIn adults with T2DM, diabetes distress improved from baseline with pramlintide.
Peptide
Pramlintide (Symlin)
Outcome
DecreaseTotal diabetes distress change
Study
n = 56
Outcome group
Quality of life · Mental health and mood
Studied dose
120 microg · 24 weeksAs given in this study (human).
Source sentences
Summary
PRAM patients experienced significant improvement in total diabetes distress, while RAIA patients did not; both groups experienced significant improvement in regimen-related distress and physician-related distress.
1 context sentence(design, population, supporting numbers)
Summary · context
In this 24-week open-label, multicenter study of adults with type 2 diabetes, mealtime pramlintide (PRAM) (120 microg fixed dose; n = 56) or titrated RAIAs (n = 56) was added to basal insulin therapy with or without oral antidiabetic medications.
Report a problemFND-2019913601
07HumanRandomized controlled trialEfficacy outcome
In adults with T2DM, sleep latency improved from baseline with pramlintide.
In plain wordsIn adults with T2DM, the time needed to fall asleep improved from baseline with pramlintide.
Peptide
Pramlintide (Symlin)
Outcome
DecreaseSleep latency
Study
n = 56
Outcome group
Sleep · Sleep
Studied dose
120 microg · 24 weeksAs given in this study (human).
Source sentences
Summary
PRAM patients experienced significant improvement in sleep latency and daytime dysfunction, while RAIA patients did not; the difference between groups was significant for daytime dysfunction.
1 context sentence(design, population, supporting numbers)
Summary · context
In this 24-week open-label, multicenter study of adults with type 2 diabetes, mealtime pramlintide (PRAM) (120 microg fixed dose; n = 56) or titrated RAIAs (n = 56) was added to basal insulin therapy with or without oral antidiabetic medications.
Report a problemFND-2019913605
08HumanRandomized controlled trialEfficacy outcome
In adults with T2DM, daytime dysfunction improved from baseline with pramlintide.
In plain wordsIn adults with T2DM, daytime dysfunction improved from baseline with pramlintide.
Peptide
Pramlintide (Symlin)
Outcome
DecreaseDaytime dysfunction change
Study
n = 56
Outcome group
Sleep · Sleep
Studied dose
120 microg · 24 weeksAs given in this study (human).
Source sentences
Summary
PRAM patients experienced significant improvement in sleep latency and daytime dysfunction, while RAIA patients did not; the difference between groups was significant for daytime dysfunction.
1 context sentence(design, population, supporting numbers)
Summary · context
In this 24-week open-label, multicenter study of adults with type 2 diabetes, mealtime pramlintide (PRAM) (120 microg fixed dose; n = 56) or titrated RAIAs (n = 56) was added to basal insulin therapy with or without oral antidiabetic medications.
Report a problemFND-2019913606
09HumanRandomized controlled trialEfficacy outcome
In adults with T2DM, perceived hypoglycemia improved from baseline only in the pramlintide group.
In plain wordsIn adults with T2DM, perceived low blood sugar improved from baseline only in the pramlintide group.
Peptide
Pramlintide (Symlin)
Outcome
Not applicablePerceived hypoglycemia
Study
n = 56
Outcome group
Quality of life · Mental health and mood
Studied dose
120 microg · 24 weeksAs given in this study (human).
Source sentences
Summary
Both treatment groups experienced significant improvement in most individual DTSQ items and total diabetes treatment satisfaction, while only PRAM patients experienced significant improvement in perceived hypoglycemia.
1 context sentence(design, population, supporting numbers)
Summary · context
In this 24-week open-label, multicenter study of adults with type 2 diabetes, mealtime pramlintide (PRAM) (120 microg fixed dose; n = 56) or titrated RAIAs (n = 56) was added to basal insulin therapy with or without oral antidiabetic medications.
Report a problemFND-2019913610

Studies that did not test the peptide alone6

In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Pramlintide (Symlin).

10HumanNot a test of Pramlintide (Symlin) aloneRandomized controlled trialEfficacy outcome
In adults with T2DM, regimen-related distress improved in both the pramlintide and rapid-acting insulin groups.
In plain wordsIn adults with T2DM, treatment-related distress improved in both the pramlintide and rapid-acting insulin groups.
Peptide
Pramlintide (Symlin)
Outcome
DecreaseRegimen-related distress change
Study
n = 112
Outcome group
Quality of life · Mental health and mood
Source sentences
Summary
PRAM patients experienced significant improvement in total diabetes distress, while RAIA patients did not; both groups experienced significant improvement in regimen-related distress and physician-related distress.
1 context sentence(design, population, supporting numbers)
Summary · context
In this 24-week open-label, multicenter study of adults with type 2 diabetes, mealtime pramlintide (PRAM) (120 microg fixed dose; n = 56) or titrated RAIAs (n = 56) was added to basal insulin therapy with or without oral antidiabetic medications.
In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pramlintide (Symlin).
Report a problemFND-2019913602
11HumanNot a test of Pramlintide (Symlin) aloneRandomized controlled trialEfficacy outcome
In adults with T2DM, physician-related distress improved in both the pramlintide and rapid-acting insulin groups.
In plain wordsIn adults with T2DM, physician-related distress improved in both the pramlintide and rapid-acting insulin groups.
Peptide
Pramlintide (Symlin)
Outcome
DecreasePhysician-related distress change
Study
n = 112
Outcome group
Quality of life · Mental health and mood
Source sentences
Summary
PRAM patients experienced significant improvement in total diabetes distress, while RAIA patients did not; both groups experienced significant improvement in regimen-related distress and physician-related distress.
1 context sentence(design, population, supporting numbers)
Summary · context
In this 24-week open-label, multicenter study of adults with type 2 diabetes, mealtime pramlintide (PRAM) (120 microg fixed dose; n = 56) or titrated RAIAs (n = 56) was added to basal insulin therapy with or without oral antidiabetic medications.
In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pramlintide (Symlin).
Report a problemFND-2019913603
12HumanNot a test of Pramlintide (Symlin) aloneRandomized controlled trialEfficacy outcome
In adults with T2DM, most individual DTSQ items improved in both pramlintide and rapid-acting insulin groups.
In plain wordsIn adults with T2DM, most treatment satisfaction items improved in both pramlintide and rapid-acting insulin groups.
Peptide
Pramlintide (Symlin)
Outcome
IncreaseDTSQ individual items
Study
n = 112
Outcome group
Quality of life · Mental health and mood
Source sentences
Summary
Both treatment groups experienced significant improvement in most individual DTSQ items and total diabetes treatment satisfaction, while only PRAM patients experienced significant improvement in perceived hypoglycemia.
1 context sentence(design, population, supporting numbers)
Summary · context
In this 24-week open-label, multicenter study of adults with type 2 diabetes, mealtime pramlintide (PRAM) (120 microg fixed dose; n = 56) or titrated RAIAs (n = 56) was added to basal insulin therapy with or without oral antidiabetic medications.
In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pramlintide (Symlin).
Report a problemFND-2019913608
13HumanNot a test of Pramlintide (Symlin) aloneRandomized controlled trialEfficacy outcome
In adults with T2DM, total diabetes treatment satisfaction improved in both pramlintide and rapid-acting insulin groups.
In plain wordsIn adults with T2DM, total treatment satisfaction improved in both pramlintide and rapid-acting insulin groups.
Peptide
Pramlintide (Symlin)
Outcome
IncreaseTotal diabetes treatment satisfaction
Study
n = 112
Outcome group
Quality of life · Mental health and mood
Source sentences
Summary
Both treatment groups experienced significant improvement in most individual DTSQ items and total diabetes treatment satisfaction, while only PRAM patients experienced significant improvement in perceived hypoglycemia.
1 context sentence(design, population, supporting numbers)
Summary · context
In this 24-week open-label, multicenter study of adults with type 2 diabetes, mealtime pramlintide (PRAM) (120 microg fixed dose; n = 56) or titrated RAIAs (n = 56) was added to basal insulin therapy with or without oral antidiabetic medications.
In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pramlintide (Symlin).
Report a problemFND-2019913609
14HumanNot a test of Pramlintide (Symlin) aloneRandomized controlled trialEfficacy outcome
In adults with T2DM, most individual PRAM-TSQ items improved in both pramlintide and rapid-acting insulin groups.
In plain wordsIn adults with T2DM, most PRAM-TSQ items improved in both pramlintide and rapid-acting insulin groups.
Peptide
Pramlintide (Symlin)
Outcome
IncreasePRAM-TSQ individual items
Study
n = 112
Outcome group
Quality of life · Mental health and mood
Source sentences
Summary
Both treatment groups experienced significant improvement in most individual PRAM-TSQ items and total treatment satisfaction; RAIA patients experienced increased eating flexibility and reduced perceived weight control.
1 context sentence(design, population, supporting numbers)
Summary · context
In this 24-week open-label, multicenter study of adults with type 2 diabetes, mealtime pramlintide (PRAM) (120 microg fixed dose; n = 56) or titrated RAIAs (n = 56) was added to basal insulin therapy with or without oral antidiabetic medications.
In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pramlintide (Symlin).
Report a problemFND-2019913612
15HumanNot a test of Pramlintide (Symlin) aloneRandomized controlled trialEfficacy outcome
In adults with T2DM, total PRAM-TSQ treatment satisfaction improved in both pramlintide and rapid-acting insulin groups.
In plain wordsIn adults with T2DM, total PRAM-TSQ treatment satisfaction improved in both pramlintide and rapid-acting insulin groups.
Peptide
Pramlintide (Symlin)
Outcome
IncreasePRAM-TSQ total satisfaction
Study
n = 112
Outcome group
Quality of life · Mental health and mood
Source sentences
Summary
Both treatment groups experienced significant improvement in most individual PRAM-TSQ items and total treatment satisfaction; RAIA patients experienced increased eating flexibility and reduced perceived weight control.
1 context sentence(design, population, supporting numbers)
Summary · context
In this 24-week open-label, multicenter study of adults with type 2 diabetes, mealtime pramlintide (PRAM) (120 microg fixed dose; n = 56) or titrated RAIAs (n = 56) was added to basal insulin therapy with or without oral antidiabetic medications.
In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pramlintide (Symlin).
Report a problemFND-2019913613

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 4Results postedNCT00467649

A Study to Characterize Regimens of Basal Insulin Intensified With Either Symlin® or Rapid Acting Insulin in Patients With Type 2 Diabetes

AstraZenecan = 112May 2007 to Apr 2008

Type 2 Diabetes Mellitus

Trial page ClinicalTrials.govUpdated 14 Apr 2015

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.